Table 2.
Black and white patient cohort: patient and tumor characteristics
| Black and white cohort pooled
analysis | ||||
|---|---|---|---|---|
| Characteristic | Neoadjuvant N (%) | Adjuvant N (%) | Total | Chi-Square (p-value) |
| All | 132 (18.21%) | 593 (81.79%) | 725 | |
| Age | ||||
| <50 | 56 (42.42%) | 189 (31.87%) | 245 | 0.02 |
| >50 | 76 (57.58%) | 404 (68.13%) | 480 | |
| Stage* | ||||
| II | 77 (58.33%) | 437 (73.69%) | 514 | 0.0004 |
| III | 55 (41.67%) | 156 (26.31%) | 211 | |
| ER status | ||||
| Negative | 68 (51.52%) | 181 (30.52%) | 249 | <0.0001 |
| Positive | 64 (48.48%) | 412 (69.48%) | 476 | |
| PR status1 | ||||
| Negative | 85 (65.38%) | 258 (43.73%) | 343 | <0.0001 |
| Positive | 45 (34.62%) | 332 (56.27%) | 377 | |
| HER2 status2 | ||||
| Equivocal | 5 (3.91%) | 0 (0.00%) | 5 | <0.0001 |
| Negative | 99 (77.34%) | 451 (78.43%) | 550 | |
| Positive | 24 (18.75%) | 124 (21.57%) | 186 | |
| Triple-negative status3 | ||||
| No | 74 (57.81%) | 443 (77.31%) | 517 | <0.0001 |
| Yes | 54 (42.19%) | 130 (22.69%) | 184 | |
*
Clinical stage was used for neoadjuvant and pathological stage for adjuvant cohort.
1
PR status missing from 4 patients: Neoadjuvant, N=131; Adjuvant, N=590.
2
HER2 status missing from 22 patients: Neoadjuvant, N=128; Adjuvant, N=575.
3
Triple-negative status missing from 24 patients: Neoadjuvant, N=128; Adjuvant, N=573
ER = estrogen receptor; PR = progesterone receptor; HER2 = Human Epidermal Growth Factor Receptor 2